| 1 |
34799380 | As Maintenance Therapy, Olaparib's Benefits Continue. | 2022 Jan |
1 |
| 2 |
34808283 | Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. | 2022 Feb 1 |
1 |
| 3 |
34924242 | Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer. | 2022 Feb |
2 |
| 4 |
35070248 | Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report. | 2022 |
1 |
| 5 |
35153073 | Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study. | 2022 Apr |
1 |
| 6 |
35207810 | Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis. | 2022 Feb 21 |
4 |
| 7 |
35326684 | Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance? | 2022 Mar 16 |
1 |
| 8 |
35404148 | BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II-IV non-small cell lung cancer: A meta-analysis. | 2022 Jun |
6 |
| 9 |
35501389 | BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors. | 2022 Apr 30 |
1 |
| 10 |
35547093 | Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis. | 2022 |
1 |
| 11 |
32827632 | Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers. | 2021 Dec |
1 |
| 12 |
33432021 | A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients. | 2021 Jan 11 |
1 |
| 13 |
33435590 | Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study. | 2021 Jan 8 |
2 |
| 14 |
33487630 | Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. | 2021 Jan |
2 |
| 15 |
33539540 | A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. | 2021 Jun 15 |
1 |
| 16 |
33559413 | A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). | 2021 Mar |
3 |
| 17 |
33662100 | Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. | 2021 May 1 |
1 |
| 18 |
33754211 | Role of Platinums in Triple-Negative Breast Cancer. | 2021 Mar 22 |
1 |
| 19 |
33804647 | Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. | 2021 Mar 20 |
1 |
| 20 |
33808149 | Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. | 2021 Mar 30 |
1 |
| 21 |
33845459 | Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma. | 2021 Apr |
2 |
| 22 |
33871703 | Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer. | 2021 Oct |
1 |
| 23 |
33896588 | Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. | 2021 Jul |
1 |
| 24 |
33929876 | Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. | 2021 Mar |
1 |
| 25 |
33941784 | Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). | 2021 May 3 |
1 |
| 26 |
34007132 | BRCA mutated pancreatic cancer: A change is coming. | 2021 May 7 |
1 |
| 27 |
34021944 | Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications. | 2021 Sep |
1 |
| 28 |
34025781 | The role of PARP inhibitors in BRCA mutated pancreatic cancer. | 2021 |
1 |
| 29 |
34068084 | The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. | 2021 May 13 |
1 |
| 30 |
34148027 | Efficacy of carboplatin chemotherapy in a metastatic, castration-resistant BRCA2 mutation positive prostate cancer patient | 2021 Jun 20 |
1 |
| 31 |
34295175 | A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer. | 2021 |
1 |
| 32 |
34337294 | Recent advances in precision medicine for pancreatic ductal adenocarcinoma. | 2021 Jul |
1 |
| 33 |
34367927 | Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors. | 2021 Jul 24 |
2 |
| 34 |
34367977 | Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells. | 2021 |
1 |
| 35 |
34417675 | Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. | 2021 Oct |
1 |
| 36 |
34454564 | Cytotoxic and targeted therapy for BRCA1/2-driven cancers. | 2021 Aug 28 |
2 |
| 37 |
34520432 | PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer. | 2021 Nov 1 |
2 |
| 38 |
34742578 | Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial. | 2021 Dec |
1 |
| 39 |
34754149 | Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance. | 2021 Oct 21 |
1 |
| 40 |
31577852 | Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. | 2020 Jan |
1 |
| 41 |
31594824 | ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers. | 2020 Jan |
1 |
| 42 |
31639439 | RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence. | 2020 Jan 1 |
1 |
| 43 |
31699415 | Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. | 2020 Jan |
1 |
| 44 |
31787750 | Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer. | 2020 Feb |
1 |
| 45 |
31787751 | Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. | 2020 Feb |
2 |
| 46 |
31797087 | Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH). | 2020 Feb |
1 |
| 47 |
31813938 | Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. | 2020 Feb |
1 |
| 48 |
31865042 | Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. | 2020 Jan |
1 |
| 49 |
32013831 | BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer. | 2020 |
2 |
| 50 |
32034076 | Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. | 2020 Jun 1 |
2 |